Development and Characterization of Mucoadhesive In Situ Nasal Gel of Midazolam Prepared with Ficus carica Mucilage

被引:0
作者
Shyamoshree Basu
Amal Kumar Bandyopadhyay
机构
[1] Jadavpur University,Department of Pharmaceutical Technology
来源
AAPS PharmSciTech | 2010年 / 11卷
关键词
midazolam hydrochloride; mucoadhesive; nasal; permeation enhancer;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of the present study was to prepare mucoadhesive in situ nasal gels with mucilage isolated from fig fruits (Ficus carica, family: Moraceae) containing midazolam hydrochloride. Nasal gels of midazolam were prepared using three different concentrations (0.5%, 1.0% and 1.5% w/v) of F. carica mucilage (FCM) and synthetic polymers (hydroxypropylmethyl cellulose and Carbopol 934). Evaluation of FCM showed that it was as safe as the synthetic polymers for nasal administration. In situ gels were prepared with mixture Pluronic F127 and mucoadhesive agents. Evaluation of the prepared gels was carried out, including determination of viscosity, texture profile analysis and mucoadhesive strength. In vitro drug permeation study was conducted with the gels prepared with and without permeation enhancer (0.5% w/v sodium taurocholate) using excised goat nasal mucosa. In vitro permeation profiles were evaluated, and histological study of nasal mucosae before and after permeation study was also conducted to determine histological change, if any. In vivo experiments conducted in rabbits further confirmed that in situ nasal gels provided better bioavailability of midazolam than the gels prepared from synthetic mucoadhesive polymers. It was observed that the nasal gel containing 0.5% FCM and 0.5% sodium taurocholate exhibited appropriate rheological, mechanical and mucoadhesive properties and showed better drug release profiles. Moreover, this formulation produced no damage to the nasal mucosa that was used for the permeation study, and absolute bioavailability was also higher compared to gels prepared from synthetic polymers.
引用
收藏
页码:1223 / 1231
页数:8
相关论文
共 119 条
[1]  
DeLorenzo RJ(1995)Epidemiology of status epilepticus J Clin Neurophysiol 12 316-25
[2]  
Pellock JM(2006)Intranasal drug delivery for children with acute illness Curr Drug Ther 1 127-30
[3]  
Towne AR(2002)Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers Br J Clin Pharmacol 54 357-62
[4]  
Boggs JG(1997)Comparison between three transmucosal routes of administration of midazolam in children Paediatr Anaesth 7 103-9
[5]  
Goldman RD(1999)Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial Lancet 353 623-6
[6]  
Pecking M(1998)Midazolam pharmacokinetics following intravenous and buccal administration Br J Clin Pharmacol 46 203-6
[7]  
Montestruc F(2001)The biopharmaceutical aspects of nasal mucoadhesive drug delivery J Pharm Pharmcol 53 3-22
[8]  
Marquet P(2002)Nasal drug delivery: new developments and strategies Drug Discov Today 7 184-9
[9]  
Wodey E(2004)Nasal route and drug delivery systems Pharm World Sci 26 137-42
[10]  
Homery MC(1999)Home and hospital treatment of acute seizures in children with nasal midazolam Eur J Paediatr Neurol 3 73-7